American Journal of Medical and Biological Research
ISSN (Print): 2328-4080 ISSN (Online): 2328-4099 Website: http://www.sciepub.com/journal/ajmbr Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Medical and Biological Research. 2015, 3(5), 133-138
DOI: 10.12691/ajmbr-3-5-3
Open AccessArticle

The Irreversible Inhibition of the MAPKp38 Pathway Downregulates LPS-augmented Release of Interleukin-Related Inflammatory Cytokines (IL-1β, IL-6): Immune Surveillance Unraveling IκB-α/NF-κB Phosphorylation State-independent Mechanism in vitro

John J Haddad1,

1Department of Medical Laboratory Sciences, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon

Pub. Date: September 02, 2015

Cite this paper:
John J Haddad. The Irreversible Inhibition of the MAPKp38 Pathway Downregulates LPS-augmented Release of Interleukin-Related Inflammatory Cytokines (IL-1β, IL-6): Immune Surveillance Unraveling IκB-α/NF-κB Phosphorylation State-independent Mechanism in vitro. American Journal of Medical and Biological Research. 2015; 3(5):133-138. doi: 10.12691/ajmbr-3-5-3

Abstract

Background: The participation of signaling pathways involving the mitogen-activated protein kinases (MAPKs) in regulating the inflammatory response characterized by the release of cytokines is not well established in the alveolar epithelium. We have previously examined the effect of MAPKp38 blockade on the in vitro release of TNF-α, indicating the likely involvement of other pro-inflammatory cytokines. Methods: This study investigated the selective inhibition of MAPKp38 in modulating the release of interleukin-related inflammatory cytokines, including IL-1β and IL-6. LPS-mediated release of cytokines is closely associated with the blockade of MAPK by the compound SB203580, an irreversible and selective inhibitor of MAPKp38, independent of MAPKERK (p42/p44) and MAPKJNK. Results: Pre-treatment with ascending concentrations of SB203580 (0.1 – 100 μM) prior to LPS administration downregulated/attenuated the release of IL-1β, IL-6 and TNF-α in a dose-dependent and dose-independent manners. Furthermore, unraveling the immune molecular pathways likely involved with MAPKp38-mediated secretion of cytokines revealed that SB203580 increased IκB-α phosphorylation, where IκB-α is considered the main cytosolic inhibitor of the transcription factor involved with regulating the processes of cellular inflammation, NF-κB. This upregulation of the phosphorylation status of IκB-α was accompanied by downregulating the cytosolic accumulation of the non-phosphorylated form of IκB-α, indicating normal nuclear translocation of the associated transcription factor. Conclusions: These results show that MAPKp38 is required, at least in part, for the release of inflammatory cytokines induced by LPS, a mechanism that is independent of the phosphorylation of IκB-α. In addition, the MAPKp38-dependent release of cytokines seemingly does not require the activation of the NF-κB pathway.

Keywords:
cytokines electrophoresis ELISA IκB-α IL-1β IL-6 inflammation MAPKs NF-κB

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Haddad, J.J., and L.B. Hanbali, 2014. Hypoxia upregulates MAPKp38/MAPKERK phosphorylation in vitro: Neuroimmunological differential time-dependent expression of MAPKs. Protein Pept. Lett., 21: 444-451.
 
[2]  Haddad, J.J., 2011. A redox microenvironment is essential for MAPK-dependent secretion of pro-inflammatory cytokines: Modulation by glutathione (GSH/GSSG) biosynthesis and equilibrium in the alveolar epithelium. Cell. Immunol., 270: 53-61.
 
[3]  Haddad, J.J., 2013. On the cellular and molecular regulatory transcriptional mechanisms and responsive putative pathways to inflammatory oxidative stress revisited: Current immunological breakthroughs and views at a glance. Antiinflamm. Antiallergy Agents Med. Chem., 12: 141-157.
 
[4]  Fernandez-Bustamante, A., Agazio, A., Wilson, P., Elkins, N., Domaleski, L., He, Q., Baer, K.A., Moss, A.F., Wischmeyer, P.E., and J.E. Repine, 2015. Brief glutamine pretreatment increases alveolar macrophage CD163/heme oxygenase-1/p38-MAPK dephosphorylation pathway and decreases capillary damage but not neutrophil recruitment in IL-1/LPS-insufflated rats. PLoS One, 10: e0130764.
 
[5]  Haddad, J.J., and N.E. Abdel-Karim, 2011. NF-κB cellular and molecular regulatory mechanisms and pathways: Therapeutic pattern or pseudoregulation? Cell. Immunol., 271: 5-14.
 
[6]  Haddad, JJ., and H.L. Harb, 2005. L-γ-Glutamyl-L-cysteinyl-glycine (glutathione; GSH) and GSH-related enzymes in the regulation of pro- and anti-inflammatory cytokines: A signaling transcriptional scenario for redox(y) immunologic sensor(s)? Mol. Immunol., 42: 987-1014.
 
[7]  Haddad, J.J., 2004. Hypoxia and the regulation of mitogen-activated protein kinases: gene transcription and the assessment of potential pharmacologic therapeutic interventions. Int. Immunopharmacol., 4: 1249-1285.
 
[8]  Haddad, J.J., 2002. Cytokines and related receptor-mediated signaling pathways. Biochem. Biophys. Res. Commun., 297: 700-713.
 
[9]  Fehr, S., Unger, A., Schaeffeler, E., Herrmann, S., Laufer, S., Schwab, M., and W. Albrecht, 2015. Impact of p38 MAP kinase inhibitors on LPS-induced release of TNF-α in whole blood and primary cells from different species. Cell. Physiol. Biochem., 36: 2237-2249.
 
[10]  Lv, H., Zhu, C., Liao, Y., Gao, Y., Lu, G., Zhong, W., Zheng, Y., Chen, W., and X. Ci, 2015. Tenuigenin ameliorates acute lung injury by inhibiting NF-κB and MAPK signalling pathways. Respir. Physiol. Neurobiol., 216: 43-51.
 
[11]  Khan, S., Shehzad, O., Cheng, M.S., Li, R.J., and Y.S. Kim, 2015. Pharmacological mechanism underlying anti-inflammatory properties of two structurally divergent coumarins through the inhibition of pro-inflammatory enzymes and cytokines. J. Inflamm. (Lond.), 12: 47.
 
[12]  Chen, H., Jiang, Y.S., Sun, Y., and Y.C. Xiong, 2015. p38 and interleukin-1 beta pathway via toll-like receptor 4 contributed to the skin and muscle incision and retraction-induced allodynia. J. Surg. Res., 197: 339-347.
 
[13]  Gupta, J., and A.R. Nebreda, 2015. Roles of p38α mitogen-activated protein kinase in mouse models of inflammatory diseases and cancer. FEBS J., 282: 1841-1857.
 
[14]  Sabio, G., and R.J. Davis, 2014. TNF and MAP kinase signalling pathways. Semin. Immunol., 26: 237-245.
 
[15]  Patterson, H., Nibbs, R., McInnes, I., and S. Siebert, 2014. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin. Exp. Immunol., 176: 1-10.
 
[16]  Peti, W., and R. Page, 2013. Molecular basis of MAP kinase regulation. Protein Sci., 22: 1698-1710.
 
[17]  Ding, Y., Yang, H., Xiang, W., He, X., Liao, W., and Z. Yi, 2015. CD200R1 agonist attenuates LPS-induced inflammatory response in human renal proximal tubular epithelial cells by regulating TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway. Biochem. Biophys. Res. Commun., 460: 287-294.